Advanced

Higher Cathepsin B Levels in Plasma in Alzheimer's Disease Compared to Healthy Controls

Sundelof, Johan; Sundstrom, Johan; Hansson, Oskar LU ; Eriksdotter-Jonhagen, Maria; Giedraitis, Vilmantas; Larsson, Anders; Degerman-Gunnarsson, Malin; Ingelsson, Martin; Minthon, Lennart LU and Blennow, Kaj, et al. (2010) In Journal of Alzheimer's Disease 22(4). p.1223-1230
Abstract
Cathepsin B is suggested to be involved in amyloid-beta (A beta) processing and Alzheimer's disease (AD). Studies of cathepsin B levels in plasma and cerebrospinal fluid (CSF) have not been previously performed. We examined cathepsin B levels in plasma and CSF samples in persons with AD, mild cognitive impairment (MCI), and healthy controls in order to test the hypothesis that cathepsin B levels can discriminate persons with AD or MCI from healthy controls. Cathepsin B, Cystatin C, A beta(1-40) and A beta(1-42), total tau, phosphorylated tau, and albumin levels in plasma and CSF were analyzed by ELISA (Cathepsin B) turbidimetry (cystatin C), xMAP Luminex technology (A beta(1-40) and A beta(1-42) and tau), and Cobas C501 analyzer (albumin)... (More)
Cathepsin B is suggested to be involved in amyloid-beta (A beta) processing and Alzheimer's disease (AD). Studies of cathepsin B levels in plasma and cerebrospinal fluid (CSF) have not been previously performed. We examined cathepsin B levels in plasma and CSF samples in persons with AD, mild cognitive impairment (MCI), and healthy controls in order to test the hypothesis that cathepsin B levels can discriminate persons with AD or MCI from healthy controls. Cathepsin B, Cystatin C, A beta(1-40) and A beta(1-42), total tau, phosphorylated tau, and albumin levels in plasma and CSF were analyzed by ELISA (Cathepsin B) turbidimetry (cystatin C), xMAP Luminex technology (A beta(1-40) and A beta(1-42) and tau), and Cobas C501 analyzer (albumin) in persons with AD (n=101), MCI (n - 84), and healthy control subjects (n - 28). Plasma cathepsin B levels were higher in persons with AD compared to healthy controls, both in unadjusted models and in multivariable models adjusting for age, gender, APOE genotype, cystatin C, and albumin levels: Odds ratio (OR) for AD per 1 SD of plasma cathepsin B; 2.04, 95% confidence interval (CI); 1.01-4.14, p = 0.05. There was no difference between diagnostic groups in cathepsin B levels in CSF: OR for AD per 1 SD of CSF cathepsin B; 0.93, 95% CI; 0.37-2.30, p = 0.87. Plasma cathepsin B levels were higher in persons with AD compared to healthy controls whereas there was no difference between diagnostic groups in cathepsin B levels in CSF. Further investigation of cathepsin B as a predictor of AD is warranted. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
risk factor, epidemiology, cystatin C, cathepsin B, case control study, biomarkers, Alzheimer's disease
in
Journal of Alzheimer's Disease
volume
22
issue
4
pages
1223 - 1230
publisher
IOS Press
external identifiers
  • wos:000286185300016
  • scopus:79751521177
ISSN
1387-2877
DOI
10.3233/JAD-2010-101023
language
English
LU publication?
yes
id
7a8064fc-baff-49bb-9caf-d2310e7a3be3 (old id 1814776)
date added to LUP
2011-03-02 13:36:32
date last changed
2018-07-08 03:00:48
@article{7a8064fc-baff-49bb-9caf-d2310e7a3be3,
  abstract     = {Cathepsin B is suggested to be involved in amyloid-beta (A beta) processing and Alzheimer's disease (AD). Studies of cathepsin B levels in plasma and cerebrospinal fluid (CSF) have not been previously performed. We examined cathepsin B levels in plasma and CSF samples in persons with AD, mild cognitive impairment (MCI), and healthy controls in order to test the hypothesis that cathepsin B levels can discriminate persons with AD or MCI from healthy controls. Cathepsin B, Cystatin C, A beta(1-40) and A beta(1-42), total tau, phosphorylated tau, and albumin levels in plasma and CSF were analyzed by ELISA (Cathepsin B) turbidimetry (cystatin C), xMAP Luminex technology (A beta(1-40) and A beta(1-42) and tau), and Cobas C501 analyzer (albumin) in persons with AD (n=101), MCI (n - 84), and healthy control subjects (n - 28). Plasma cathepsin B levels were higher in persons with AD compared to healthy controls, both in unadjusted models and in multivariable models adjusting for age, gender, APOE genotype, cystatin C, and albumin levels: Odds ratio (OR) for AD per 1 SD of plasma cathepsin B; 2.04, 95% confidence interval (CI); 1.01-4.14, p = 0.05. There was no difference between diagnostic groups in cathepsin B levels in CSF: OR for AD per 1 SD of CSF cathepsin B; 0.93, 95% CI; 0.37-2.30, p = 0.87. Plasma cathepsin B levels were higher in persons with AD compared to healthy controls whereas there was no difference between diagnostic groups in cathepsin B levels in CSF. Further investigation of cathepsin B as a predictor of AD is warranted.},
  author       = {Sundelof, Johan and Sundstrom, Johan and Hansson, Oskar and Eriksdotter-Jonhagen, Maria and Giedraitis, Vilmantas and Larsson, Anders and Degerman-Gunnarsson, Malin and Ingelsson, Martin and Minthon, Lennart and Blennow, Kaj and Kilander, Lena and Basun, Hans and Lannfelt, Lars},
  issn         = {1387-2877},
  keyword      = {risk factor,epidemiology,cystatin C,cathepsin B,case control study,biomarkers,Alzheimer's disease},
  language     = {eng},
  number       = {4},
  pages        = {1223--1230},
  publisher    = {IOS Press},
  series       = {Journal of Alzheimer's Disease},
  title        = {Higher Cathepsin B Levels in Plasma in Alzheimer's Disease Compared to Healthy Controls},
  url          = {http://dx.doi.org/10.3233/JAD-2010-101023},
  volume       = {22},
  year         = {2010},
}